Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Kobold, Sebastian ^a   Steffen, Julius ^a   Chaloupka, Michael ^a   Grassmann, Simon ^a   Henkel, Jonas ^a   Castoldi, Raffaella ^b   Zeng, Yi ^a   Chmielewski, Markus ^c   Schmollinger, Jan C ^a   Schnurr, Max ^a   Rothenfußer, Simon ^a   Schendel, Dolores J ^d   Abken, Hinrich ^c   Sustmann, Claudio ^b   Niederfellner, Gerhard ^b   Klein, Christian ^e   Bourquin, Carole ^a,f   Endres, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e Roche Pharmaceutical Research and Early Development Oncology Discovery and Translational Area Roche Innovation Center Zurich   (Switzerland)

^f UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; MONOPHENOL MONOOXYGENASE; SCATTER FACTOR RECEPTOR; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR; CELL ADHESION MOLECULE; EGFR PROTEIN, HUMAN; EPCAM PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL KILLING; COLON CANCER; CONTROLLED STUDY; GASTRIC CANCER CELL LINE; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOG RANK TEST; LYMPHOCYTIC INFILTRATION; MELANOMA; MELANOMA CELL; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; STOMACH CANCER; STUDENT T TEST; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; VIRUS STRAIN; WILD TYPE; ANIMAL; C57BL MOUSE; GENETIC TRANSDUCTION; IMMUNOLOGY; METABOLISM; STOMACH NEOPLASMS; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; STOMACH NEOPLASMS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 84925546776     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju364     Document Type: Article

References (30)

1. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269-281.
2. Chinnasamy D, Yu Z, Theoret MR, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest. 2010;120(11):3953-3968.
3. Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol. 1995;25(4):1071-1079.
4. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24(4):363-373.
5. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550-4557.
6. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233-5239.
7. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
8. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974-977.
9. Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209-2221.
10. Riechelmann H, Wiesneth M, Schauwecker P, et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother. 2007;56(9):1397-1406.
11. Hombach A, Wieczarkowiecz A, Marquardt T, et al. Tumorspecific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol. 2001;167(11):6123-6131.
12. Leisegang M, Engels B, Meyerhuber P, et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med. 2008;86(5):573-583.
13. Mueller K, von Massenhausen A, Aichele U, et al. Protective capacity of virus-specific T cell receptor-transduced CD8 T cells in vivo. J Virol. 2012;86(19):10866-10869.
14. Bourquin C, von der Borch P, Zoglmeier C, et al. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model. J Immunol. 2010;185(4):2580-2588.
15. Luo FR, Yang Z, Dong H, et al. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemother Pharmacol. 2005;56(5):455-464.
16. Castoldi R, Ecker V, Wiehle L, et al. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene. 2013;32(50):5593-5601.
17. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994;24(3):759-764.
18. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225(1):1-26.
19. Amann M, Brischwein K, Lutterbuese P, et al. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res. 2008;68(1):143-151.
20. Sampson JH, Crotty LE, Lee S, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A. 2000;97(13):7503-7508.
21. Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013;280(21):5350-5370.
22. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-1221.
23. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95(7):1592-1600.
24. Nitta T, Sato K, Yagita H, Okumura K, Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet. 1990;335(8686):368-371.
25. Buhmann R, Simoes B, Stanglmaier M, et al. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20(FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant. 2009;43(5):383-397.
26. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
27. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.
28. Goldstein N, Giorgio NA, Jones ST, Saldanha JW. Antibody and antibody fragments for inhibiting the growth of tumors. In: Organization WIP, ed. 1996.
29. Castoldi R, Jucknischke U, Pradel LP, et al. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Eng Des Sel. 2012;25(10):551-559.
30. Panke C, Weininger D, Haas A, et al. Quantification of cell surface proteins with bispecific antibodies. Protein Eng Des Sel. 2013;26(10):645-654.